Floatz logo

USISTAPIDE

Nutrition Disorders

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Nutrition Disorders cohort.

Asset / SponsorPhaseRating
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Intralipid
Johane Allard
Phase 4BB
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Lamivudine
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB

View all 33 →

Same molecule, other indications

USISTAPIDE is also rated in:

metabolic diseaseDormant
BB
Indicative ·
67 / 100
View asset →
type 2 diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →
diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →